NCT00002787View on ClinicalTrials.gov

Vaccine Therapy in Treating Patients With Multiple Myeloma Who Have Undergone Stem Cell Transplantation

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

March 31, 1996

Primary Completion Date

December 31, 2002

Conditions

Refractory Multiple MyelomaStage I Multiple MyelomaStage II Multiple MyelomaStage III Multiple Myeloma

Interventions

BIOLOGICAL

autologous immunoglobulin idiotype-KLH conjugate vaccine

Given SC

BIOLOGICAL

sargramostim

Given SC

BIOLOGICAL

aldesleukin

Given SC

OTHER

laboratory biomarker analysis

Correlative studies

Trial Locations (1)

98109

Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle

All Listed Sponsors

collaborator

National Cancer Institute (NCI)

NIH

lead

Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium

OTHER

NCT00002787 - Vaccine Therapy in Treating Patients With Multiple Myeloma Who Have Undergone Stem Cell Transplantation | Biotech Hunter | Biotech Hunter